Zacks: Brokerages Expect Bruker Co. (BRKR) Will Announce Quarterly Sales of $410.24 Million

Equities research analysts predict that Bruker Co. (NASDAQ:BRKR) will post sales of $410.24 million for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Bruker’s earnings, with estimates ranging from $393.50 million to $420.67 million. Bruker posted sales of $384.90 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.6%. The business is expected to issue its next earnings results on Wednesday, May 2nd.

On average, analysts expect that Bruker will report full year sales of $410.24 million for the current year, with estimates ranging from $1.82 billion to $1.89 billion. For the next fiscal year, analysts expect that the company will post sales of $1.94 billion per share, with estimates ranging from $1.87 billion to $1.98 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Bruker.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.02. Bruker had a return on equity of 26.58% and a net margin of 4.45%. The company had revenue of $530.50 million for the quarter, compared to analysts’ expectations of $506.74 million. During the same period in the previous year, the firm posted $0.46 earnings per share. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis.

Several equities research analysts have weighed in on BRKR shares. BTIG Research started coverage on Bruker in a research note on Friday, January 5th. They set a “buy” rating and a $42.00 price objective on the stock. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Thursday, January 4th. BidaskClub cut Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Morgan Stanley reissued an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a research note on Thursday, December 14th. Finally, Cowen reissued a “hold” rating and set a $35.00 price objective on shares of Bruker in a research note on Thursday, December 21st. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $32.29.

Shares of Bruker (BRKR) opened at $31.43 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. Bruker has a 52 week low of $21.83 and a 52 week high of $36.53. The firm has a market capitalization of $4,758.66, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 2.23 and a beta of 1.05.

Large investors have recently made changes to their positions in the business. Bank of Montreal Can boosted its position in shares of Bruker by 346.7% during the fourth quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock valued at $128,000 after buying an additional 2,878 shares during the period. Zions Bancorporation purchased a new position in shares of Bruker during the third quarter valued at approximately $119,000. SG Americas Securities LLC purchased a new position in shares of Bruker during the fourth quarter valued at approximately $145,000. The Manufacturers Life Insurance Company boosted its position in shares of Bruker by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after buying an additional 331 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bruker by 43.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,586 shares of the medical research company’s stock valued at $226,000 after buying an additional 1,987 shares during the period. Institutional investors and hedge funds own 64.78% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/13/zacks-brokerages-expect-bruker-co-brkr-will-announce-quarterly-sales-of-410-24-million.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply